Osmotica Pharmaceuticals has named Praveen Tyle, its chief scientific officer, as the international drug firm’s new chief executive officer.
Tyle succeeds R. Forrest Waldon, who had been the CEO for the past seven years. Waldon will remain a board member and serve as an adviser to the company.
“Praveen has proven in a short tenure at the company that he has the talent and exceptional executive leadership skills to take our company to greater heights and growth,” the board of directors said in a joint statement. “He is an exemplary leader with strategic vision and operational excellence needed for the next phase of Osmotica.”
Tyle has 30 years of experience in the life science industry. He joined Osmotica last August. Earlier in his career he worked at Pharmacopeia, Novartis and Bausch + Lomb.
